论文部分内容阅读
本文采用定量聚合酶链反应（PCR）检测了327例乙型肝炎及肝癌患者血清HBVDNA含量和部分病例治疗前后其含量的变化。结果显示，但肝组＞急肝组，且均明显高于肝硬化组，肝癌组与肝硬化组相似；HBeAg（+）组血清HBVDNA含量明显高于HBeAg（-）组；血清HBVDNA含量与黄疸及转氨酶无关。特异性过继细胞免疫疗法治疗后完全反应者、部分反应者及无反应者其血清HBVDNA含量变化不同。结果表明：血清HBVDNA含量高低与肝炎疾病进展程度呈一定的相关性，而与肝细胞损伤程度无关；定量检测HBVDNA含量是评价特异性过继细胞免疫疗法疗效的重要指标之一。
In this paper, quantitative polymerase chain reaction (PCR) was used to detect the serum HBVDNA content of 327 patients with hepatitis B and hepatocellular carcinoma and its changes in some patients before and after treatment. The results showed that, but the liver group> acute liver group, and were significantly higher than the cirrhosis group, liver cancer group and cirrhosis group similar; HBeAg (+) serum HBVDNA group was significantly higher than the HBeAg (-) group; serum HBVDNA content and jaundice And aminotransferase has nothing to do. Specific adoptive cell immunotherapy complete response after treatment, some responders and non-responders serum HBVDNA content varies. The results showed that serum HBVDNA levels correlated with the degree of progression of hepatitis and had no correlation with the degree of hepatocyte injury. Quantitative detection of HBVDNA content was one of the important indexes to evaluate the efficacy of specific adoptive cell immunotherapy.